Cargando…
Reported Benefits of Low-Dose Naltrexone Appear to Be Independent of the Endogenous Opioid System Involving Proopiomelanocortin Neurons and β-Endorphin
Naltrexone is an opioid receptor antagonist approved for the treatment of alcohol and opioid use disorders at doses of 50–150 mg/d. Naltrexone has also been prescribed at much lower doses (3–6 mg/d) for the off-label treatment of inflammation and pain. Currently, a compelling mechanistic explanation...
Autores principales: | Metz, Marissa J., Daimon, Caitlin M., Hentges, Shane T. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Society for Neuroscience
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8211470/ https://www.ncbi.nlm.nih.gov/pubmed/34031099 http://dx.doi.org/10.1523/ENEURO.0087-21.2021 |
Ejemplares similares
-
GPN-1/glypican and UNC-52/perlecan do not appear to function in BMP signaling to pattern the C. elegans postembryonic mesoderm
por: DeGroot, Melisa S, et al.
Publicado: (2021) -
No apparent role for the Wari insulator in transcriptional regulation of the endogenous
white
gene of
Drosophila melanogaster
por: Born, Gordian, et al.
Publicado: (2023) -
Glucagon-Like Peptide-1 Receptor Agonist Treatment Does Not Reduce Abuse-Related Effects of Opioid Drugs
por: Bornebusch, Annika Billefeld, et al.
Publicado: (2019) -
No Evidence for Sex Differences in the Electrophysiological Properties and Excitatory Synaptic Input onto Nucleus Accumbens Shell Medium Spiny Neurons123
por: Willett, Jaime A., et al.
Publicado: (2016) -
Deletion of Ripk3 Prevents Motor Neuron Death In Vitro but not In Vivo
por: Dermentzaki, Georgia, et al.
Publicado: (2019)